SI-BONE, Inc. (SIBN)

SI-BONE is growing quickly (FY2025 revenue $200.93M, +20% YoY; ~22.18% 5-year revenue CAGR) and maintains very high gross margins (~79–80%), but it is still unprofitable (TTM net margin -8.10%, EBITDA margin -2.90%) with negative free cash flow (TTM FCF yield -0.73%). Liquidity is strong (TTM current ratio ~9.99; SEC filings indicate ~$145–148M cash and marketable securities) and there is no disclosed going-concern warning. A key uncertainty is regulatory/legal: the Q1 2026 10-Q discloses an ongoing DOJ investigation (CID) related to healthcare professional payments. Valuation is best viewed on sales (EV/Sales ~3.55x) given negative earnings; both analyst targets and DCF-style estimates imply upside, but execution and the DOJ outcome are central to the thesis.

Last ~14d coverage is thin and mostly bullish technical-analysis commentary (one rumored technical catalyst), while the 30–90d baseline was modestly positive on Q1 results/analyst-upside recaps, implying a roughly flat sentiment delta. With no confirmed forward-dated company catalyst and an unresolved DOJ CID disclosure as a moderate overhang, the setup is neutral and score is capped at 3.

Bullish structure is intact because the last daily close is above SMA20/50/200, EMA9/21, and VWAP, while MACD is positive above its signal and ADX confirms a strong trend. The chart stops short of a top score because 2026-06-30 was a heavy-volume pullback day and near-term resistance sits in the 17.47-17.88 zone.